Dacomitinib Found Not to Improve Overall Survival in Patients with Advanced NSCLC

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal The Lancet Oncology, researchers have found that dacomitinib, an irreversible pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), was not effective at improving overall survival in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy and an epidermal growth factor (EGFR) TKI.

In the phase 3 double-blind, placebo-controlled study, researchers randomly assigned 720 patients to receive either dacomitinib or placebo. Patients treated with dacomitinib were followed for a median of 23.4 months and patients given placebo were followed for a median of 24.4 months.

They found that patients in the dacomitinib group had a median overall survival 6.83 months, while those in the placebo group had an overall survival of 6.21 months (HR 1.00 [95% CI 0.83-1.21]; P=0.506). Patients in the dacomitinib group had progression-free survival nearly twice as long as the placebo group (median 2.66 months versus 1.38 months, respectively; HR 0.66 [95% CI 0.55-0.79]; P<0.0001). Patients taking dacomitinib had a longer time to worsening of lung cancer symptoms than the placebo group.

The findings suggest that dacomitinib should not be recommended for the treatment of patients with advanced NSCLC previously treated with chemotherapy and an EGFR TKI.

For Advanced Non-Small Cell Lung Cancer (NSCLC), Nintedanib Improves Overall Survival Without Reduci
Dacomitinib was not effective at improving overall survival in advanced NSCLC.
The authors designed BR.26 to assess whether dacomitinib improved overall survival in heavily pretreated patients with this disease. Dacomitinib did not increase overall survival and cannot be recommended for treatment of patients with advanced non-small-cell lung cancer previously treated with chemotherapy and an EGFR tyrosine-kinase inhibitor.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs